Teva Settlements Stick To Date of Entry Even As Legislative Debate Continues
Executive Summary
Teva is taking a cautious approach in its patent settlements with brand firms - inking deals that meet the strict standards of pending legislation even as the bills are still under debate
You may also be interested in...
Lipitor Generics Problem Illustrates Need For Hatch-Waxman Reform, Academics Say
Even with revised use-it-or-lose it provisions, exclusivity parking is still prevalent and won't be prevented by banning "pay-for-delay" settlements, David Balto and Michael Carrier argue.
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired
Patent Settlement Bill Advances - And Firms Fight Back With Examples Of Early Generic Launches That Would Be Prohibited
Four years ago, Teva inked a patent litigation settlement with Wyeth that enabled it to launch generic Effexor XR seven years before the patent on the drug expired